Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 35Lymphoma 10Leukemia, B-Cell 10Leukemia 9Recurrence 8Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Neoplasms 5Bronchiolitis Obliterans Syndrome 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 2Hodgkin Disease 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Prolymphocytic 1Leukemia, Lymphoid 1Fever 1Fatigue 1Disease 1Agammaglobulinemia 1

Interventions

ibrutinib 5fludarabine 4Rituximab 4Lenalidomide 3Busulfan 3thymoglobulin 2fludarabine phosphate 2blinatumomab 2Vincristine 2Methotrexate 2Melphalan 2Bendamustine Hydrochloride 2Behavior Therapy 2Alemtuzumab 2tozasertib 1sargramostim 1romiplostim 1pirtobrutinib 1pegaspargase 1palbociclib 1ofatumumab 1obinutuzumab 1mocetinostat 1lirilumab 1forodesine 1fenebrutinib 1enzastaurin 1duvelisib 1Stem Cell Transplantation 1RFT5-SMPT-dgA immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Lymphoid × ofatumumab × Clear all
NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Novartis

Phase 2 Completed
99 enrolled 27 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡